Related Experiment Video
Updated: Jul 2, 2026
10:18
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
Published on: October 19, 2014
13.7K
A Clinical Perspective on Plasma Cell Leukemia: A Single-Center Experience
Andrew Y Li1, Farin Kamangar2, Noa G Holtzman3
1University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD 21201, USA.
Cancers
|June 19, 2024
Summary
Plasma cell leukemia (PCL) patients have circulating plasma cells (CPCs) and a poor prognosis. Despite various treatments, the 5-year survival remains low at 11%, highlighting the urgent need for better therapeutic options.
Area of Science:
- Hematology
- Oncology
- Clinical Research
Background:
- Circulating plasma cells (CPCs) are common in multiple myeloma (MM), but plasma cell leukemia (PCL) signifies a distinct, aggressive subtype.
- PCL presents as primary (pPCL) or secondary (sPCL) and is associated with poor patient outcomes.
Purpose of the Study:
- To evaluate the clinical characteristics, treatment patterns, and survival outcomes of patients with plasma cell leukemia (PCL).
- To identify factors associated with poor prognosis in PCL.
Main Methods:
- Retrospective analysis of patients with primary or secondary PCL, including those with ≥5% and 1-4% circulating plasma cells (CPCs).
- Data collected on patient demographics, cytogenetics, disease characteristics, treatments received (proteasome inhibitors, chemotherapy, immunomodulatory drugs, daratumumab, ASCT), and survival.
Main Results:
- The cohort (n=104) had a median age of 61, with 47% having extramedullary disease and 87% high-risk cytogenetics.
- While treatments like proteasome inhibitors and chemotherapy were common, overall survival was poor, with a 5-year survival of 11%.
- Primary PCL showed marginally better survival (13 months) than secondary PCL (3.5 months). High-risk cytogenetics, low platelets, extramedullary disease, and high LDH were linked to worse outcomes.
Conclusions:
- Plasma cell leukemia (PCL) remains a challenging hematologic malignancy with dismal survival rates despite current therapies.
- Urgent development of novel treatment strategies is required to improve outcomes for PCL patients.
- Identifying prognostic factors aids in risk stratification and understanding the disease's aggressive nature.
